US FDA clarifies new device listing and registration rules, effective October
This article was originally published in Clinica
The US Food and Drug Administration has issued a document to help medical device establishments comply with new product registration and listing requirements that will come into effect on 1 October.
You may also be interested in...
The risk of psychiatric disorders with chloroquine and hydroxychloroquine-containing medicines received renewed attention in the EU after they were being used as potential treatments for COVID-19.
New UK guidance explains how clinical trial sponsors and investigator sites can ensure that trial monitors securely process data in electronic health record systems that do not have a restricted access functionality.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.